Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness and population outcomes of general population screening for hepatitis C.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 1 May 2012

Coffin Phillip O, Scott John D, Golden Matthew R, Sullivan Sean D

Abstract excerpt

BACKGROUND: Current US guidelines recommend limiting hepatitis C virus (HCV) screening to high-risk individuals, and 50%-75% of infected persons remain unaware of their status. METHODS: To estimate the cost-effectiveness and population-level impact of adding one-time HCV screening of US population aged 20-69 years to current guidelines, we developed a decision analytic model for the screening intervention and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Decision Support Techniques

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Liver Cirrhosis

Share to Markov Chains

Share to Mass Screening

Share to Protease Inhibitors

Share to Quality-Adjusted Life Years

Source

Open in PubMed Open full text

Identifiers

PMID: 22412061
DOI: 10.1093/cid/cis011
PMCID: PMC3404694

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness and population outcomes of general population screening for hepatitis C.PMID 22412061Read ↗

Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea.Semantic proximity Read ↗

The changing burden of hepatitis C virus infection in the United States: model-based predictions.Semantic proximity Read ↗

Cost and cost-effectiveness of alternative screening and diagnostic pathways for achieving hepatitis C elimination in the country of GeorgiaSemantic proximity Read ↗

Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.Semantic proximity Read ↗

The Cost-effectiveness of One-step Point-of-care Hepatitis C Virus RNA Testing in the United StatesSemantic proximity Read ↗

Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling studySemantic proximity Read ↗

Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs.Semantic proximity Read ↗

Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.Semantic proximity Read ↗

The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.Semantic proximity Read ↗

Economic assessment of an anti-HCV screening program in Italy.Semantic proximity Read ↗

New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.Semantic proximity Read ↗

Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.